Editor’s note: This story is developing. Stay tuned for more information on the verdict and its implications for the single-cell sequencing market.
10x Genomics announced on Aug. 28 that a Delaware jury has awarded it $4.8 million in damages after finding that Qiagen subsidiary Parse Biosciences infringed single-cell sequencing patents held by 10x.
The damages cover sales of Parse’s Evercode Whole Transcriptome products from February 2021 through June 30, 2026 and are based on a 14 percent royalty rate on Parse sales. In a statement, 10x said it will seek additional damages and a permanent injunction in the US.
The verdict gives 10x, already the dominant force in the single-cell sequencing market, an even stronger position. 10x has also sued Illumina, which acquired single-cell isolation technology via Fluent Biosciences in 2024, alleging patent infringement.
How Parse will respond remains to be seen. The company did not immediately respond to a request for comment.
The patents at suit were licensed by single-cell startup Scale Biosciences from Roche Sequencing Solutions and became part of 10x’s patent portfolio after it bought Scale in August 2025 for $30 million plus undisclosed milestones. Scale sued Parse prior to being acquired; both companies use a combinatorial barcoding approach to tagging transcripts in a single cell.
Qiagen acquired Parse in late 2025 for $225 million in cash with up to $55 million in additional milestones.
“I started working on these inventions more than a decade ago and I’m incredibly proud of how they’ve expanded what’s possible with single cell analysis,” Scale cofounder Garry Nolan, also a researcher at Stanford University, said in a statement. “Today’s verdict is a win for inventors. It affirms that original ideas matter and that strong patent rights are essential to advancing science.”
In a statement, 10x Chief Legal Officer Randy Wu said he was “pleased” with the verdict.